RETATRUTIDE PEN 30 MG
Generic Name: Retatrutide
Category: Investigational triple receptor agonist
Administration: Subcutaneous use

Important note: Retatrutide remains an investigational medicine and is not approved by regulatory agencies for commercial use. Lilly states it is legally available only through its clinical trials.

PRODUCT NAME & PACKAGING

Product Name: Retatrutide Pen
Generic Name: Retatrutide
Strength & Packaging: 30 mg

Product Details

• 30 mg retatrutide per pre-filled pen
• Stabilised, pH-balanced solution
• Designed for subcutaneous administration
• Precision dosing via click-based system

What’s Included

• 1 × Pre-filled FlexiPen (30 mg Retatrutide)
• 1 × Instruction leaflet
• 20 × Pen needles (5 mm, 31G)

Packaging note: The above pack contents are presented as provided. They are not part of an FDA-approved commercial labeling standard because retatrutide is still investigational.

DESCRIPTION

Retatrutide is an investigational once-weekly injectable peptide being studied for its potential role in weight management and metabolic disease. It is a single molecule designed to activate three hormone pathways: GIP, GLP-1, and glucagon. Clinical development remains ongoing, and safety and efficacy continue to be evaluated in Phase 3 trials.

INDICATIONS

Approved indications: None established.

Therapeutic areas under investigation include:

• Obesity or overweight with weight-related complications
• Type 2 diabetes
• Knee osteoarthritis
• Obstructive sleep apnea
• Chronic low back pain
• Cardiovascular and renal outcomes
• Metabolic dysfunction-associated steatotic liver disease

These should be described as clinical research indications only, not approved uses.

DOSAGE & ADMINISTRATION

Route: Subcutaneous administration

Administration Overview
This presentation is designed for subcutaneous use through a pre-filled pen device with a click-based dosing system. Because retatrutide is investigational, there is no approved commercial dosage regimen. In Lilly materials, retatrutide is described as a once-weekly subcutaneous injection in clinical trials.

MECHANISM OF ACTION

Retatrutide is a triple agonist that activates receptors for:

• GIP (glucose-dependent insulinotropic polypeptide)
• GLP-1 (glucagon-like peptide-1)
• Glucagon

This multi-receptor activity is being studied for effects on body weight, glycemic control, and broader cardiometabolic outcomes.

PRECAUTIONS

• For investigational use only
• Not approved for routine prescribing or commercial therapeutic use
• Safety and efficacy are still under evaluation
• Products claiming to be retatrutide outside authorized study channels may present safety and authenticity risks

Lilly specifically warns that no one should consider taking anything claiming to be retatrutide outside a Lilly-sponsored clinical trial.

SIDE EFFECTS

Reported adverse events in Lilly’s recent Phase 3 update included:

• Nausea
• Diarrhea
• Vomiting

These were reported mainly during dose escalation. Lilly also noted dysesthesia in a minority of participants, generally described as mild in the reported study update.

STORAGE

Storage: Store between 2–8°C. Do not freeze.